Exhibit 99


        CardioDynamics Announces Two Significant Clinical Presentations
              at American College of Cardiology Scientific Meeting

    SAN DIEGO--(BUSINESS WIRE)--March 10, 2004--

      ICG Highlighted in Comprehensive Heart Failure Session

    CardioDynamics (Nasdaq:CDIC), the innovator and leader of
Impedance Cardiography (ICG) technology, today announced two
significant clinical presentations at the American College of
Cardiology 53rd Scientific Sessions in New Orleans demonstrating
Impedance Cardiography's (ICG) accuracy and value in management of
heart failure patients. Clyde Yancy M.D., FACC, Medical Director of
Heart Failure/Heart Transplantation, at the University of Texas
Southwestern Medical Center & St. Paul University Hospital, Dallas,
Texas, and a leading heart failure specialist, presented to a group of
over 500 cardiologists and other heart care professionals featuring
ICG as an important noninvasive method in diagnosing and managing
heart failure.
    Dr. Yancy's presentation covered ICG's accuracy, clinical
applications for identification, titration and management of drugs,
recently released clinical studies, and upcoming clinical trial work
demonstrating new clinical applications for ICG. The Point of Care
Heart Failure session spanned over three hours and included
presentations from leading heart failure specialists, including Lynne
Warner Stevenson, M.D. F.A.C.C., Director, Cardiomyopathy Service,
Brigham and Women's Hospital, Boston, MA, Monica R. Shah, M.D.,
Assistant Professor of Medicine, Duke University Medical Center,
Durham, NC, and Uri Elkayam, M.D., F.A.C.C., Director, Heart Failure
Program, University of Southern California, Keck School of Medicine,
Los Angeles, CA.
    Also presented were the results of a clinical study by Marcellus
Francis L. Ramirez, M.D., of the University of Santo Tomas, Manila,
Philippines, demonstrating the value of ICG in the detection of left
ventricular systolic dysfunction and correlation with the
echocardiogram (echo). The study collected two different ICG
parameters: velocity index (VI), an indicator of peak blood velocity
as it leaves the heart, and acceleration index (ACI), a measure of
peak blood acceleration as it leaves the heart. VI and ACI parameters
reflect the pumping ability of the heart muscle and in this study were
compared to the ejection fraction (EF) as determined by an echo. There
was 70% sensitivity and 73% specificity, which mean that when there
was impaired pumping ability (systolic dysfunction), ICG showed it 70%
of the time. When there was normal heart pumping ability (preserved
systolic function), ICG showed it 73% of the time. The study
concluded, "Impedance cardiography is useful in the noninvasive
hemodynamic assessment of heart failure patients. Patients with
systolic dysfunction demonstrate a low acceleration index and a low
velocity index by ICG, while those with normal systolic function show
normal values in both parameters."
    The results of this study suggest that the BioZ may be a valuable
and cost-effective tool when compared to the more costly echo test.
ICG technology can also provide important measures of heart pumping
ability between echo testing, which is typically limited by insurance
companies and Medicare to once every six months or one year. There are
additional ongoing studies evaluating the effectiveness of ICG
compared to the echo for screening patients who are at risk for heart
failure.
    "We are pleased and encouraged by the increasing levels of
interest in ICG from the medical community at this year's ACC
conference. In one session alone, we had our largest audience ever,
with over 500 cardiologists and clinicians learning about ICG's value.
Additionally, while a significant amount of evidence substantiating
ICG's clinical application is now available, we are encouraged by the
number of ongoing studies, presentations and publications which will
be available over the next six to 18 months," stated Michael K. Perry,
CardioDynamics' CEO. "Clinical evidence is ultimately the primary
basis for which our customers determine whether they need ICG
technology. Our strategy is to continue to expand evidence of the
technology's validity and clinical application in our target markets."
    In addition, the Company met with investigators from the PREDICT
(Prospective Evaluation and Identification of Decompensation by ICG
Test) study to review statistical analysis of the Company's
multi-center study in heart failure. PREDICT is a prospective study
focused on the early detection of patients with congestive heart
failure. The primary goal of PREDICT is to identify ICG parameters
which will be used to anticipate and intervene in high risk patients
to prevent emergency room visits, hospitalizations and premature
deaths. The Company anticipates the results of this significant
21-center study to be submitted for presentation at the Annual Heart
Failure Society of America Meeting being held September 12-15, 2004 in
Toronto, Canada.

    About CardioDynamics:

    CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator
and leader of breakthrough medical technology called Impedance
Cardiography (ICG). The Company's BioZ Systems are being used by
leading physicians around the world to help battle the number one
killer of men and women -- cardiovascular disease. Partners include GE
Medical Systems Information Technologies and Philips Medical Systems.
The worldwide market potential for BioZ products is estimated to be $5
billion and an additional $800 million in recurring annual revenue for
sensors. For additional information or to request an investor package,
please refer to the company's Web site at www.cdic.com.

    Forward-Looking (Safe Harbor) Statement:

    Except for the historical and factual information contained
herein, this press release contains forward-looking statements, such
as market size, potential, growth and penetration rates, the accuracy
of which is necessarily subject to uncertainties and risks including
the Company's sole dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as
other risks detailed in the Company's filings with the SEC, including
its 2003 Form 10-K. The Company does not undertake to update the
disclosures contained in this press release.


    CONTACT: CardioDynamics
             Bonnie Ortega, 888-522-2342, Ext. 1005 (IR)
             bortega@cardiodynamics.com
             Irene Paigah, 888-522-2342, Ext. 1012 (Media Relations)
             ipaigah@cardiodynamics.com